Kenneth O'Byrne

Queensland University of Technology

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cancer Biology Cancer Biology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Mark Adams

Queensland University of Technology

AUSTRALIA

View details

Emma Bolderson

Senior Research Fellow / Senior Lecturer

Queensland University of Technology

AUSTRALIA

View details

Judith Bushong

Bristol-Myers Squibb

UNITED STATES

View details

Alistair Cook

University of Western Australia

AUSTRALIA

View details

Willem Joost Lesterhuis

University of Western Australia

AUSTRALIA

View details

Arutha Kulasinghe

Queensland University of Technology

AUSTRALIA

View details

Kienan Savage

Reader/Group Leader

The Queen's University Belfast

UNITED KINGDOM

View details

Heidi Roschitzki-Voser

Head Trial Activities

SWITZERLAND

View details

Derek Richard

Queensland University of Technology

AUSTRALIA

View details

Amila Suraweera

Research Fellow/Lecturer

Queensland University of Technology

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kenneth O'Byrne

Research Interests

Explore related searches

Contact this professor

Articles (13)

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial

Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)

The Role of Circulating Biomarkers in Lung Cancer

The Pandora’s box of novel technologies that may revolutionize lung cancer

Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review

Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy

Barrier-To-Autointegration-factor (Banf1) modulates DNA double-strand break repair pathway choice via regulation of DNA-dependent kinase (DNA-PK) activity

COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks

Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?

Collaborators (10)

Mark Adams

Emma Bolderson

Judith Bushong

Alistair Cook

Willem Joost Lesterhuis

Arutha Kulasinghe

Kienan Savage

Heidi Roschitzki-Voser

Derek Richard

Amila Suraweera

Make your next move.